Kevesy (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release and stabilizes neuronal excitability. This action reduces the likelihood of abnormal electrical discharges that cause seizures, though the exact downstream mechanisms are not fully understood.

The specific dose of Kevesy is determined by the prescribing clinician based on the patient’s age, weight, renal function, and clinical situation. Healthcare professionals set the appropriate infusion rate and total daily amount according to established guidelines.

The safety of levetiracetam in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare provider.

To order Kevesy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Kevesy (levetiracetam) offers a favorable safety profile, minimal protein binding, and limited drug‑drug interactions compared with many traditional IV antiepileptics such as phenytoin or phenobarbital. Its rapid onset and ease of dosing make it a preferred option for acute seizure management in many clinical settings.

Kevesy should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before administration, inspect for particulate matter or discoloration and use aseptic technique.

Kevesy is given by intravenous infusion. The rate and duration are determined by the prescriber, typically over 15 minutes to an hour, depending on the clinical scenario and patient tolerance.

Serious risks include severe allergic reactions, Stevens‑Johnson syndrome, blood dyscrasias, suicidal thoughts, and respiratory depression, especially when combined with other central nervous system depressants. Prompt recognition and medical intervention are essential if these events occur.

Kevesy is contraindicated in patients with known hypersensitivity to levetiracetam or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those receiving incompatible IV solutions.